Liang Liu

Liang Liu

Auto-generated profile, based on publicly available information

Liang Liu

Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing 100053, China

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2024 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
JCJianbo Cheng
Jianbo Cheng
ZWZhen Wang
Zhen Wang
MTManpei Tang
Manpei Tang
WZWen Zhang
Wen Zhang
GLGuozhong Li
Guozhong Li
LYLing Yuan
Ling Yuan
KCTD10 belongs to the KCTD (potassiumchannel tetramerization domain) family, many members of which are associated with neuropsychiatric disorders. However, the biological function underlying the association with brain disorders remains to be explored. Here, we reveal that Kctd10 is highly expressed in neuronal progenitors and layer V neurons throughout brain development.Kctd10deficiency triggers abnormal proliferation and differentiation of neuronal progenitors, reduced deep-layer (especially layer V) neurons, increased upper-layer neurons, and lowered brain size. Mechanistically, we screened and identified a unique KCTD10-interacting protein, KCTD13, associated with neurodevelopmental disorders. KCTD10 mediated the ubiquitination-dependent degradation of KCTD13 and KCTD10 ablation resulted in a considerable increase of KCTD13 expression in the developing cortex. KCTD13 overexpression in neuronal progenitors led to reduced proliferation and abnormal cell distribution, mirroring KCTD10 deficiency. Notably, mice with brain-specificKctd10knockout exhibited obvious motor deficits. This study uncovers the physiological function of KCTD10 and provides unique insights into the pathogenesis of neurodevelopmental disorders.

20 November 2024 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
CMChenjun Mu
Chenjun Mu
PLPan Liu
Pan Liu
LLLiang Liu
Liang Liu
YWYaqing Wang
Yaqing Wang
KLKefu Liu
Kefu Liu
LYLing Yuan
Ling Yuan
KCTD10, a member of the potassium channel tetramerization domain (KCTD) family, is implicated in neuropsychiatric disorders and functions as a substrate recognition component within the RING-type ubiquitin ligase complex. A rare de novo variant of KCTD10, p.C124W, was identified in schizophrenia cases, yet its underlying pathogenesis remains unexplored. Here, we demonstrate that heterozygous KCTD10 C124W mice display pronounced synaptic abnormalities and exhibit schizophrenia-like behaviors. Mechanistically, we reveal that KCTD10 undergoes liquid–liquid phase separation (LLPS), a process orchestrated by its intrinsically disordered region (IDR). p.C124W mutation disrupts this LLPS capability, leading to diminished degradation of RHOB and subsequent excessive accumulation in the postsynaptic density fractions. Notably, neither IDR deletion nor p.C124W mutation in KCTD10 mitigates the synaptic abnormalities caused by Kctd10 deficiency. Thus, our findings implicate that LLPS may be associated with the pathogenesis of KCTD10-associated brain disorders and highlight the potential of targeting RHOB as a therapeutic strategy for diseases linked to mutations in KCTD10 or RHOB.

18 June 2026 in EBioMedicine
Verified
Journal Article
Open access
QWQi Wang
Qi Wang
FCFeng Chen
Feng Chen
YTYuqi Tang
Yuqi Tang
JZJuanjuan Zhang
Juanjuan Zhang
ZSZhengyu Sun
Zhengyu Sun
LLLiang Liu
Liang Liu
Live cell-based assay (LCBA) is the gold standard for sensitive detection of aquaporin-4 (AQP4) and myelin oligodendrocyte glycoprotein (MOG) autoantibodies in neuromyelitis optica spectrum disorder (NMOSD) and MOG antibody-associated disorder (MOGAD). However, LCBA is less practical, standardisable and cost-effective than fixed cell-based assay (FCBA). We developed a high-performance untransfected vector cells lysate, named AbFine, to process patients' sera to pre-bind and deplete interferents before FCBA, and examined its rationality. We then conducted a multicentre, double-blind, prospective discovery study to compare the diagnostic accuracy of conventional FCBA, FCBA-AbFine, and LCBA in detecting AQP4-IgG and MOG-IgG. A retrospective validation cohort was used to assess generalisability. Participants included patients with NMOSD, MOGAD, and seronegative inflammatory demyelination syndromes, and controls with other neurological disorders. 818 participants were recruited, including 410 in the discovery and 408 in the validation cohorts with good consistency. Among 205 patients with NMOSD, AQP4-IgG was detected in 165, 185, and 178 by FCBA, FCBA-AbFine, and LCBA, yielding sensitivity of 80.5% (95% CI, 74.4-85.7), 90.2% (95% CI, 85.3-93.9), and 86.8% (95% CI, 81.4-91.1), respectively. Among 171 patients with MOGAD, MOG-IgG was found in 134, 155, and 158 by FCBA, FCBA-AbFine, and LCBA, with sensitivity of 78.4% (95% CI, 71.4-84.3), 90.6% (95% CI, 85.3-94.6), and 92.4% (95% CI, 87.4-95.9), respectively. All assays achieved specificity greater than 99.5%. The area under the curve for FCBA-AbFine was higher than that for FCBA for both AQP4-IgG (0.950 vs. 0.902; p < 0.0001) and MOG-IgG (0.935 vs. 0.888; p < 0.05), and was comparable to LCBA (AQP4-IgG 0.950 vs. 0.934; MOG-IgG 0.935 vs. 0.940; p > 0.05 for both). AbFine enables the use of FCBA as an alternative to LCBA in AQP4-IgG and MOG-IgG detection with operationally practical and cost-efficient characteristics and could be extended to other fixed cellular assays. Beijing Precigen Biopharma Co., Ltd., Beijing, China.

24 April 2026 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
XWXiao Wang
Xiao Wang
YHYating Hu
Yating Hu
LLLu Liu
Lu Liu
RHRunze Huang
Runze Huang
YWYawei Wang
Yawei Wang
XCXiaowei Chen
Xiaowei Chen
The biogenesis and transport of lipoproteins are essential for systemic homeostasis and cardiometabolic health, yet how the secretory pathway acquires specialization to support high-capacity lipoprotein export remains unclear. Here, we report SEC16B as a tissue-selective modulator of the COPII machinery, critical for the efficient secretion of APOB-containing lipoproteins. Integrative bioinformatic analyses identify that SEC16B co-emerges with core genes involved in lipoprotein biogenesis. Functional studies, coupled with AI-driven prediction, reveal that SEC16B acts as a molecular brake to fine-tune COPII condensation for lipoprotein export. Mining of UK biobank data links SEC16B to metabolic traits in humans and suggests HNF4A-dependent regulation of SEC16B expression. Hepatic deletion of SEC16B in mice markedly reduces circulating APOB, triglycerides and cholesterol, while conferring robust protection against atherosclerosis and cardiac dysfunction and maintaining liver health. Collectively, these findings position SEC16B as a specialized modulator of lipoprotein export via the general secretory (SEC) pathway in the liver, suggesting potential therapeutic avenues for combating cardiometabolic diseases.